PENICILLIN V CALCIUM

First approved in 1955

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C16H17N2O5S.Ca
Molecular Weight	738.841
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC3=CC=CC=C3)C([O-])=O.[H][C@]45SC(C)(C)[C@@H](N4C(=O)[C@H]5NC(=O)COC6=CC=CC=C6)C([O-])=O

InChI

InChIKey=NPTZOUGIOYWQFI-ANPZCEIESA-L

InChI=1S/2C16H18N2O5S.Ca/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;;+2/p-2/t2*11-,12+,14-;/m11./s1

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H17N2O5S
Molecular Weight	349.382
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00417
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf

Penicillin V is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Penicillin V has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Penicillin V results from the inhibition of cell wall synthesis and is mediated through Penicillin V binding to penicillin binding proteins (PBPs). Penicillin V is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor. Used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Staphylococcus aureus 67 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16495241	Inhibitor 8297
Penicillin-binding protein 1A 45 Target ID: Q8XJ01 Gene ID: 990276.0 Gene Symbol: pbpA Target Organism: Clostridium perfringens (strain 13 / Type A) Sources: http://www.drugbank.ca/drugs/DB00417	Inhibitor 8297
Penicillin-binding protein 2a 17 Target ID: CHEMBL3512 Sources: http://www.drugbank.ca/drugs/DB00417	Inhibitor 8297
Streptococcus pneumoniae 25 Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3172134	Inhibitor 8297
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: http://www.genome.jp/dbget-bin/www_bget?D05411+D00497+D08360	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Pneumococcal infections 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Curative	Approved 8429	Penicillin V Approved Use Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date 1990
Streptococcal infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Curative	Approved 8429	Penicillin V Approved Use Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date 1990
Staphylococcal infections 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Curative	Approved 8429	Penicillin V Approved Use Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date 1990

C_max

Value	Dose	Analyte	Population
15 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
35.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
19.01 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.36 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.94 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.89 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219	0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered:	PENICILLIN V POTASSIUM serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	unknown, oral		PENICILLIN V POTASSIUM serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9006528 Page: p.48	unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: https://pubmed.ncbi.nlm.nih.gov/9006528 Page: p.48	Disc. AE: Stomach cramps, Nausea... Other AEs: Diarrhea, Rash... AEs leading to discontinuation/dose reduction: Stomach cramps (0.46%) Nausea (0.46%) Other AEs: Diarrhea (0.8%) Rash (1.2%) Abdominal pain (0.8%) Infection (1.7%) Headache (1.2%) Vomiting (2.5%) Rhinitis (1.2%) Gastroenteritis (0.4%) Epistaxis (0.4%) Ear pain (2.1%) Cough increased (1.2%) Nausea (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/9006528 Page: p.48
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1656738 Page: p.3A-25S	unhealthy, 16+ n = 117 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 16+ Sex: M+F Population Size: 117 Sources: https://pubmed.ncbi.nlm.nih.gov/1656738 Page: p.3A-25S	Disc. AE: Abdominal pain... AEs leading to discontinuation/dose reduction: Abdominal pain (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/1656738 Page: p.3A-25S
590 mg 3 times / day multiple, oral Recommended Dose: 590 mg, 3 times / day Route: oral Route: multiple Dose: 590 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11815577 Page: p.341	unhealthy, 28+/-7.9 n = 113 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 28+/-7.9 Sex: M+F Population Size: 113 Sources: https://pubmed.ncbi.nlm.nih.gov/11815577 Page: p.341	Disc. AE: Nausea, Taste alteration... AEs leading to discontinuation/dose reduction: Nausea (grade 3, 0.88%) Taste alteration (grade 3, 0.88%) Sources: https://pubmed.ncbi.nlm.nih.gov/11815577 Page: p.341
800 mg 4 times / day multiple, oral Highest studied dose Dose: 800 mg, 4 times / day Route: oral Route: multiple Dose: 800 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	unhealthy, 30.0 (6–73) n = 212 Health Status: unhealthy Condition: Pharyngotonsillitis caused by group A streptococci Age Group: 30.0 (6–73) Sex: M+F Population Size: 212 Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	Sources: https://pubmed.ncbi.nlm.nih.gov/31585944
1 g 3 times / day multiple, oral Recommended Dose: 1 g, 3 times / day Route: oral Route: multiple Dose: 1 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	unhealthy, 31.0 (3–67) n = 210 Health Status: unhealthy Condition: Pharyngotonsillitis caused by group A streptococci Age Group: 31.0 (3–67) Sex: M+F Population Size: 210 Sources: https://pubmed.ncbi.nlm.nih.gov/31585944	Sources: https://pubmed.ncbi.nlm.nih.gov/31585944
3 g multiple, oral Recommended Dose: 3 g Route: oral Route: multiple Dose: 3 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf Page: p.2	unhealthy Health Status: unhealthy Condition: Prophylaxis against bacterial endocarditis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf Page: p.2	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf Page: p.2
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1428189 Page: p.70/306	unhealthy n = 175 Health Status: unhealthy Condition: Streptococcal pharyngitis\|Streptococcal tonsillitis Sex: M+F Population Size: 175 Sources: https://pubmed.ncbi.nlm.nih.gov/1428189 Page: p.70/306	Disc. AE: Rash, Vomiting... AEs leading to discontinuation/dose reduction: Rash (0.57%) Vomiting (0.57%) Sources: https://pubmed.ncbi.nlm.nih.gov/1428189 Page: p.70/306
500 mg 4 times / day multiple, oral (max) Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf Page: p.2	unhealthy Health Status: unhealthy Condition: Infections due to penicillin G sensitive microorganisms Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf Page: p.2	Disc. AE: Hypersensitivity reaction, Diarrhea, Clostridium difficile... AEs leading to discontinuation/dose reduction: Hypersensitivity reaction (serious\|grade 5) Diarrhea, Clostridium difficile (mild\|grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf Page: p.2

AEs

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-053377	http://www.3bsc.com/index/pro_info.php?id=91842
AHH Chemical co.,ltd	MT-57705	http://www.ahhchemical.com/product/MT-57705.html
Alfa Chemistry	AP87081	https://reagents.alfa-chemistry.com/product/penicillin-v-cas-87-08-1-17587.html
Aurora Fine Chemicals LLC	A17.930.778	http://online.aurorafinechemicals.com/info?ID=A17.930.778
Aurora Fine Chemicals LLC	K14.717.682	http://online.aurorafinechemicals.com/info?ID=K14.717.682
Avantor Inc	101095-750	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101095-750
BLD Pharm	BD290184	http://www.bldpharm.com/products/87-08-1.html
BioSynth	W-109316	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/W-109316.html
Glentham Life Sciences	GA2160	http://www.glentham.com/products/product/GA2160/
Hairui	HR140122	http://www.hairuichem.com/en/product/87-08-1.html
LGC Standards	DRE-A16045500AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16045500AL-100
LGC Standards	DRE-C16045500	https://www.lgcstandards.com/US/en/p/DRE-C16045500
Lab Network	LN01343665	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343665
MuseChem	R062176	https://www.musechem.com/product/R062176.html
Sigma-Aldrich	P1000000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/p1000000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1504489_USP	https://www.sigmaaldrich.com/catalog/product/usp/1504489?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S571986	https://www.smolecule.com/products/s571986
THE BioTek	bt-311879	https://www.thebiotek.com/product/others/bt-311879

PubMed

Title	Date	PubMed
[The antiviral activity of the antibiotics beromycin and carminomycin].	1974 Feb	4219122
[Immune hemolytic anemia and thrombocytopenia after peroral therapy with a penicillin derivative (phenoxymethylpenicillin)].	1977	415731
Assessment of the "E' book as a tool for drug monitoring.	1981 Mar	6790651
[Leukocytoclastic vasculitis due to drug allergy presenting as generalized pustular exanthema].	1981 Sep	6268571
Effect of drugs influencing synthesis of prostaglandins on haloperidol-induced catalepsy in rats.	1984 Jul-Sep	6440863
Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy.	1990 Nov	1701026
Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in an adult population.	1992 Jun 22	1621750
Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.	2005	16332143
Penicillin V, loracarbef and clindamycin in tonsillar surface fluid during acute group A streptococcal pharyngotonsillitis.	2005	16012002
Antigen specific quantification of sulfidoleukotrienes in patients allergic to Betalactam antibiotics.	2005	15864881
Relationships between skin test, specific IgE and levels of cytokines in patients with penicillin allergy.	2005 Aug	16033609
Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillins allergy.	2005 Aug	15969687
Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V.	2005 Dec	16393332
Differential effects of beta-lactams on human IFN-gamma activity.	2005 Dec	16239287
Community prescribing and resistant Streptococcus pneumoniae.	2005 Jun	15963276
Analysis of phenoxymethylpenicillin potassium by capillary electrophoresis.	2005 Sep 16	16130714
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.	2006	22500153
Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin.	2006	16484823
Clinical practice. Antibiotic allergy.	2006 Feb 9	16467547
Facilitated column selection in pharmaceutical analyses using a simple column classification system.	2006 Jan 6	16242136
HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins.	2006 Mar 20	16584643
[Express determination of beta-lactam antibiotics in biological matter with potentiometric sensors].	2007	20583465
[The microbiology of peritonsillar abscesses].	2007	18510073
Hypersensitivity to penicillin V with good tolerance to other beta-lactams.	2007	17323864
Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers.	2007 Dec	18184536
Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin.	2007 Jul	17510067
Dishing the dirt on asthma: What we can learn from poor hygiene.	2007 Jun	19707324
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.	2007 Jun	17446241
Leukocyte counts in urine reflect the risk of concomitant sepsis in bacteriuric infants: a retrospective cohort study.	2007 Jun 13	17567901
Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients.	2007 Mar	17225142
Evaluation of phenoxymethylpenicillin treatment of acute otitis media in children aged 2-16.	2007 Sep	17846935
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.	2008 Aug	18505790
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008 Dec	19337440
[Summary of the practice guideline 'Sore throat' (second revision) from the Dutch College of General Practitioners].	2008 Feb 23	18361191
Antimicrobial susceptibility of periodontopathogenic bacteria.	2008 May	18326855
A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya.	2008 Nov 18	19017387
Drug use in children: cohort study in three European countries.	2008 Nov 24	19029175
Antistreptococcal treatment of guttate psoriasis: a controlled study.	2008 Sep	18937661
Treatment of Lyme borreliosis.	2009	20067594
SDRIFE (baboon syndrome) induced by penicillin.	2009 Apr	18699835
Antibiotic prescribing in paediatric populations: a comparison between Viareggio, Italy and Funen, Denmark.	2009 Aug	19349289
Specific IgG antibodies in sera in patients with penicillin allergy.	2009 Jun	19067119
Acute tonsillopharyngitis in a family practice in Mostar, Bosnia and Herzegovina.	2009 Mar	19408639
Decreased Streptococcus pneumoniae susceptibility to oral antibiotics among children in rural Vietnam: a community study.	2010 Mar 31	20356399
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.	2010 Nov	21139869
How are antibacterials used in nursing homes? Results from a point-prevalence prescription study in 44 Norwegian nursing homes.	2010 Oct	20712026
Prevalence of Group A b-Hemolytic Streptococcus Among Children with Tonsillopharyngitis in Kyrgyzstan: The Difficulty of Diagnostics and Therapy.	2010 Oct 13	21253454
Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells.	2012 Aug 1	22609641
Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity.	2012 Feb	22112502
Synthesis of novel hapten and production of generic monoclonal antibody for immunoassay of penicillins residues in milk.	2013	23452214

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bacterial Infection Mild to moderate infections: 125 to 500 mg orally every 6 to 8 hours

Route of Administration: Oral

In Vitro Use Guide

Penicillin V inhibited Staphylococcus aureus in human THP-1 macrophages (intracellular) with MIC90 of 0.015 mg/L

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:37:56 GMT 2023` Edited by `admin` on `Fri Dec 15 18:37:56 GMT 2023`
Record UNII	3750YH4NM7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PENICILLIN V CALCIUM

Common Name

English

PENICILLIN V CALCIUM SALT [MI]

Common Name

English

PHENOXYMETHYLPENICILLIN CALCIUM

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENOXYACETYL)AMINO)-, CALCIUM SALT (2:1), (2S,5R,6R)-

Common Name

English

PHENOXYMETHYLPENICILLIN CALCIUM [MART.]

Common Name

English

PENICILLIN V CALCIUM SALT

Common Name

English

Phenoxymethylpenicillin calcium [WHO-DD]

Common Name

English

Code System Code Type Description

SMS_ID

100000085276